MCID: END035
MIFTS: 50

Endocrine Gland Cancer

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Endocrine Gland Cancer

MalaCards integrated aliases for Endocrine Gland Cancer:

Name: Endocrine Gland Cancer 12 14
Malignant Neoplasm of Endocrine Gland 12 69
Endocrine Gland Neoplasms 42 69
Endocrine Neoplasm 12 52
Malignant Tumour of Endocrine Gland 12
Neoplasm of the Endocrine System 29
Neoplasm of Endocrine System 12
Carcinoma of Endocrine Gland 69
Neoplasm of Endocrine Gland 12
Malignant Endocrine Tumor 12
Endocrine Cancer 52
Endocrine Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:170
ICD10 33 C75.9
ICD9CM 35 194.9
MeSH 42 D004701
NCIt 47 C3010 C3575

Summaries for Endocrine Gland Cancer

Disease Ontology : 12 An organ system cancer located in endocrine system that is characterized by uncontrolled cellular proliferation of the hormone producing glands of the endocrine system.

MalaCards based summary : Endocrine Gland Cancer, also known as malignant neoplasm of endocrine gland, is related to pancreatic somatostatinoma and pheochromocytoma. An important gene associated with Endocrine Gland Cancer is RET (Ret Proto-Oncogene), and among its related pathways/superpathways are Signaling by GPCR and Endometrial cancer. The drugs Ethanol and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include thyroid, pancreas and breast, and related phenotypes are Decreased viability and homeostasis/metabolism

Related Diseases for Endocrine Gland Cancer

Diseases related to Endocrine Gland Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 177)
id Related Disease Score Top Affiliating Genes
1 pancreatic somatostatinoma 30.6 AREG HRAS KRAS
2 pheochromocytoma 30.2 CALCA CHGA RET SDHB SST SYP
3 non-functioning pancreatic endocrine tumor 12.1
4 functioning pancreatic endocrine tumor 12.0
5 bronchial endocrine tumor 11.8
6 pancreatic neuroendocrine tumor 11.6
7 islet cell tumor 11.2
8 malignant ovarian mixed epithelial neoplasm 11.1 CHGA SYP
9 ampulla of vater small cell carcinoma 11.1 CHGA SYP
10 spinal cord ependymoma 11.1 CHGA SYP
11 autoimmune enteropathy 11.1 CHGA GAST
12 renal pelvis carcinoma 11.1 CHGA GNAS SST
13 rete ovarii cystadenofibroma 11.1 CHGA SST SYP
14 ludwig's angina 11.1 CHGA SYP
15 signet ring cell intrahepatic cholangiocarcinoma 11.1 CHGA SYP
16 cowden syndrome 3 11.1 CHGA SST SYP
17 early-onset parkinson disease 11.1 RET SST SYP
18 childhood mediastinal neurogenic tumor 11.1 CALCA TG
19 pemphigus foliaceus 11.1 CALCA SST SYP
20 glutamate decarboxylase deficiency 11.1 CHGA SST VIP
21 wegmann jones smith syndrome 11.0 CALCA SST VIP
22 childhood choriocarcinoma of the ovary 11.0 CHGA SYP
23 parietal lobe neoplasm 11.0 CALCA CHGA TG
24 chronic polyneuropathy 11.0 HRAS RET TG
25 primary syphilis 11.0 CHGA GAST SST
26 synovitis 11.0 ESR1 SYP
27 bone giant cell sarcoma 11.0 CHGA GAST SST
28 malignant skin fibrous histiocytoma 11.0 HRAS KRAS
29 parachordoma 11.0 KRAS RET TG
30 breast apocrine carcinoma in situ 11.0 SST SYP
31 central nervous system hematologic cancer 11.0 AR CHGA SYP
32 congenital mesoblastic nephroma 11.0 CHGA KRAS SYP
33 neuroendocrine tumor of the colon 11.0 CALCA GAST
34 demyelinating polyneuropathy 11.0 HRAS RET TG
35 fibroma 11.0 GNAS KRAS SST
36 central nervous system melanocytic neoplasm 11.0 AR CHGA SYP
37 osteogenesis imperfecta 11.0 AR CYP19A1 ESR1
38 fallopian tube papillary adenocarcinoma 11.0 CHGA ESR1 RET SYP
39 basal cell carcinoma 7 11.0 CHGA CYP19A1 SYP
40 limb ischemia 11.0 HRAS KRAS SST
41 perianal skin paget's disease 11.0 CHGA GAST SYP
42 nodular prostate 11.0 CALCA RET TG
43 tricuspid valve prolapse 11.0 CALCA CHGA VIP
44 extrinsic cardiomyopathy 11.0 CHGA SST SYP
45 osteoblastoma 11.0 CHGA SYP
46 cavernous hemangioma 11.0 CHGA RET SYP VIP
47 pandas 11.0 CALCA GAST SST
48 primary progressive multiple sclerosis 11.0 CHGA GAST SST
49 bladder cancer, childhood 11.0 CHGA SST SYP VIP
50 worth's syndrome 11.0 CALCA GNAS SST

Graphical network of the top 20 diseases related to Endocrine Gland Cancer:



Diseases related to Endocrine Gland Cancer

Symptoms & Phenotypes for Endocrine Gland Cancer

GenomeRNAi Phenotypes related to Endocrine Gland Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.97 HRAS KRAS
2 Decreased viability GR00106-A-0 9.97 KRAS
3 Decreased viability GR00221-A-1 9.97 KDR RET KRAS ESR1 HRAS
4 Decreased viability GR00221-A-2 9.97 KRAS KDR RET ESR1 HRAS
5 Decreased viability GR00221-A-3 9.97 KDR HRAS
6 Decreased viability GR00221-A-4 9.97 KDR RET ESR1
7 Decreased viability GR00231-A 9.97 RET
8 Decreased viability GR00301-A 9.97 KRAS RET
9 Decreased viability GR00381-A-1 9.97 KRAS

MGI Mouse Phenotypes related to Endocrine Gland Cancer:

44 (show all 17)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.41 KDR KRAS MLH1 RET SST TG
2 endocrine/exocrine gland MP:0005379 10.38 GNAS HRAS KRAS MLH1 RET SDHB
3 cardiovascular system MP:0005385 10.34 AR AREG CHGA CYP19A1 ESR1 GNAS
4 growth/size/body region MP:0005378 10.34 AR AREG CHGA CYP19A1 ESR1 GNAS
5 behavior/neurological MP:0005386 10.31 AR CYP19A1 ESR1 GNAS HRAS KDR
6 mortality/aging MP:0010768 10.3 AR AREG CHGA ESR1 GAST GNAS
7 immune system MP:0005387 10.27 AREG CYP19A1 ESR1 GAST AR GNAS
8 digestive/alimentary MP:0005381 10.2 SST AR AREG CYP19A1 ESR1 GAST
9 nervous system MP:0003631 10.14 TG AR CYP19A1 ESR1 GNAS HRAS
10 integument MP:0010771 10.13 AR AREG CYP19A1 ESR1 GNAS HRAS
11 normal MP:0002873 10.1 AR CYP19A1 ESR1 GNAS HRAS KDR
12 neoplasm MP:0002006 10.09 AR ESR1 GAST GNAS HRAS KRAS
13 no phenotypic analysis MP:0003012 9.97 ESR1 GNAS HRAS KDR KRAS RET
14 renal/urinary system MP:0005367 9.86 AR CHGA CYP19A1 ESR1 GNAS HRAS
15 reproductive system MP:0005389 9.81 CHGA CYP19A1 ESR1 KRAS MLH1 RET
16 respiratory system MP:0005388 9.56 ESR1 GNAS HRAS KDR KRAS MLH1
17 skeleton MP:0005390 9.28 AR CYP19A1 ESR1 GNAS HRAS IAPP

Drugs & Therapeutics for Endocrine Gland Cancer

Drugs for Endocrine Gland Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 861)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
4
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
5
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
6
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
7
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
8
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 95058-81-4 60750
9
Morphine Approved, Investigational Phase 4 57-27-2 5288826
10
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 169590-42-5 2662
11
Ibuprofen Approved Phase 4 15687-27-1 3672
12
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
13
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 6442177
14
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
15
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
16
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
17
Menthol Approved Phase 4,Phase 2,Phase 1,Early Phase 1 2216-51-5 16666
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
19
Secretin Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1 108153-74-8
20
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 216974-75-3
21
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
22
Pancrelipase Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 53608-75-6
23
Somatostatin Approved Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
24
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 763113-22-0 23725625
25
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 9005-49-6 772 46507594
26
Nicotine Approved Phase 4 54-11-5 942 89594
27
Zinc Approved Phase 4,Phase 2 7440-66-6 32051 23994
28
Iron Approved Phase 4,Phase 2 7439-89-6 23925
29
Acetaminophen Approved Phase 4 103-90-2 1983
30
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
31
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2 50-23-7 5754 657311
32
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
33
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
34
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
35
Tranexamic Acid Approved Phase 4 1197-18-8 5526
36
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
37
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
38
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
39
Dexlansoprazole Approved Phase 4 138530-94-6, 103577-45-3 9578005
40
Dalteparin Approved Phase 4,Phase 3,Phase 2,Phase 1 9005-49-6
41
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
42
Tegafur Approved Phase 4,Phase 2,Phase 1 17902-23-7 5386
43
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
44
Thrombin Approved Phase 4
45
Desflurane Approved Phase 4 57041-67-5 42113
46
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 11103-57-4, 68-26-8 445354
47
Vitamin C Approved, Nutraceutical Phase 4,Phase 2,Phase 1,Early Phase 1 50-81-7 5785 54670067
48
Iodine Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7553-56-2 807
49 Pancreatic Polypeptide Investigational Phase 4,Phase 2,Phase 3,Phase 1 59763-91-6
50
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703

Interventional clinical trials:

(show top 50) (show all 3777)

id Name Status NCT ID Phase Drugs
1 rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors Unknown status NCT00902122 Phase 4 rAd-p53 gene;p53 gene therapy
2 Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms Unknown status NCT01673334 Phase 4
3 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
4 Efficacy of Secretin MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis Unknown status NCT01845467 Phase 4
5 Total Thyroidectomy With Harmonic Scalpel® Unknown status NCT00385983 Phase 4
6 Characterization of Receptors in Non-functioning Pituitary Macroadenomas Unknown status NCT00852501 Phase 4
7 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
8 Dental Safety Profile of High-Dose Radioiodine Therapy Completed NCT00439478 Phase 4 Radioiodine
9 Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer Completed NCT00604318 Phase 4 rhTSH
10 A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours Completed NCT01736163 Phase 4 Thyrogen;131I
11 Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer Completed NCT01346410 Phase 4
12 Tumor Gene Expression in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
13 Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Completed NCT00966277 Phase 4 Dalteparin
14 Tranexamic Acid in Surgery of Advanced Ovarian Cancer Completed NCT00740116 Phase 4 Tranexamic acid;0.9% NaCl solution
15 Taste, Smell and Chemotherapy (TASTY) Completed NCT01641172 Phase 4
16 Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI) Completed NCT00920023 Phase 4 Superparamagnetic Iron Oxide Magnetic Resonance Imaging
17 A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
18 Effects of Dexmedetomidine During IRE Procedures for Solid Tumours Completed NCT02044224 Phase 4 Dexmedetomidine
19 A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer Completed NCT00037518 Phase 4 AMG 073
20 Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal. Completed NCT00001730 Phase 4 Thyrogen
21 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
22 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
23 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4 Lansoprazole (Prevacid)
24 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
25 Standard and Immunostimulating Enteral Nutrition in Surgical Patients Completed NCT00576940 Phase 4 Reconvan;Peptisorb
26 The Impact of Immunostimulating Nutrition on the Outcome of Surgery Completed NCT00558155 Phase 4 peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven
27 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
28 Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi Completed NCT01041612 Phase 4
29 Prospective Study of Celiac Block Injection: 1 vs. 2 Completed NCT00583479 Phase 4
30 Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia Completed NCT01308320 Phase 4 fentanyl citrate;saline
31 RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction Completed NCT00980889 Phase 4
32 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
33 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
34 RCT: Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses Completed NCT02092519 Phase 4
35 Radiolabeled Molecules for Medullary Thyroid Cancer Recruiting NCT01915485 Phase 4
36 Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy Recruiting NCT02946918 Phase 4 Levothyroxine
37 Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. Recruiting NCT01953107 Phase 4
38 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Recruiting NCT02476968 Phase 4 Olaparib
39 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
40 Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach Recruiting NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
41 CTC Pancreatic Adenocarcinoma Recruiting NCT02335151 Phase 4 Desflurane
42 Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer Recruiting NCT01774019 Phase 4
43 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients Recruiting NCT02812992 Phase 4 Nab-paclitaxel;Gemcitabine
44 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Recruiting NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
45 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
46 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
47 The Effect of Application of TachoSil® in Pancreatoduodenectomy Recruiting NCT03269955 Phase 4 Fibrinogen/thrombin-coated collagen patch
48 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
49 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
50 To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer Active, not recruiting NCT01496313 Phase 4 300mg vandetanib;150mg vandetanib

Search NIH Clinical Center for Endocrine Gland Cancer

Cochrane evidence based reviews: endocrine gland neoplasms

Genetic Tests for Endocrine Gland Cancer

Genetic tests related to Endocrine Gland Cancer:

id Genetic test Affiliating Genes
1 Neoplasm of the Endocrine System 29

Anatomical Context for Endocrine Gland Cancer

MalaCards organs/tissues related to Endocrine Gland Cancer:

39
Thyroid, Pancreas, Breast, Lung, Testes, T Cells, Pituitary

Publications for Endocrine Gland Cancer

Articles related to Endocrine Gland Cancer:

id Title Authors Year
1
Endocrine gland cancer. ( 8001005 )
1995

Variations for Endocrine Gland Cancer

Expression for Endocrine Gland Cancer

Search GEO for disease gene expression data for Endocrine Gland Cancer.

Pathways for Endocrine Gland Cancer

Pathways related to Endocrine Gland Cancer according to GeneCards Suite gene sharing:

(show all 20)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 AR CALCA ESR1 GAST GCG GNAS
2
Show member pathways
12.3 AR ESR1 HRAS KDR KRAS MLH1
3
Show member pathways
12.28 CALCA GCG GNAS IAPP
4
Show member pathways
12.27 ESR1 HRAS KDR KRAS
5 12.23 AR GNAS HRAS KRAS MLH1 RET
6
Show member pathways
12.21 GAST HRAS KDR KRAS
7 12.17 ESR1 HRAS KDR KRAS
8
Show member pathways
12.05 AREG HRAS KDR KRAS
9 11.95 AR CYP19A1 ESR1 KRAS
10 11.54 HRAS KRAS RET
11 11.52 CALCA GCG GNAS IAPP VIP
12 11.48 GNAS HRAS KRAS
13
Show member pathways
11.48 HRAS KDR KRAS RET
14
Show member pathways
11.32 AR ESR1 GCG
15 11.26 AR CALCA CYP19A1
16 10.86 ESR1 HRAS KRAS
17 10.71 HRAS KRAS
18 10.61 ESR1 HRAS KRAS RET
19 10.36 GAST VIP
20 9.97 CYP19A1 ESR1

GO Terms for Endocrine Gland Cancer

Cellular components related to Endocrine Gland Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 AREG CALCA CHGA GAST GCG IAPP
2 extracellular region GO:0005576 9.32 CALCA CHGA GAST GCG GNAS IAPP

Biological processes related to Endocrine Gland Cancer according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.85 AR AREG HRAS KDR KRAS VIP
2 cell-cell signaling GO:0007267 9.8 AR AREG CALCA IAPP SST
3 epidermal growth factor receptor signaling pathway GO:0007173 9.65 AREG HRAS KRAS
4 positive regulation of cAMP biosynthetic process GO:0030819 9.63 CALCA GCG GNAS
5 negative regulation of bone resorption GO:0045779 9.52 CALCA IAPP
6 response to isolation stress GO:0035900 9.51 HRAS KRAS
7 prostate gland growth GO:0060736 9.49 AR CYP19A1
8 epithelial cell proliferation involved in mammary gland duct elongation GO:0060750 9.43 AREG ESR1
9 positive regulation of MAPK cascade GO:0043410 9.43 AR HRAS KDR
10 regulation of long-term neuronal synaptic plasticity GO:0048169 9.33 HRAS KRAS SYP
11 mammary gland alveolus development GO:0060749 9.13 AR AREG ESR1
12 positive regulation of cAMP metabolic process GO:0030816 8.32 CHGA
13 signal transduction GO:0007165 10.02 AR ESR1 GAST GCG GNAS HRAS

Molecular functions related to Endocrine Gland Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.17 CALCA GAST GCG IAPP SST TG

Sources for Endocrine Gland Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....